Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2008 2
2010 1
2011 1
2012 1
2013 2
2014 1
2015 2
2016 2
2017 1
2018 2
2019 2
2020 2
2021 7
2022 5
2023 8
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, Tai DW, Lim HY, Yau T, Yong WP, Cheng AL, Gasbarrini A, Damian S, Bruix J, Borad M, Bendell J, Kim TY, Standifer N, He P, Makowsky M, Negro A, Kudo M, Abou-Alfa GK. Kelley RK, et al. Among authors: damian s. J Clin Oncol. 2021 Sep 20;39(27):2991-3001. doi: 10.1200/JCO.20.03555. Epub 2021 Jul 22. J Clin Oncol. 2021. PMID: 34292792 Free PMC article. Clinical Trial.
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG. Drilon A, et al. Among authors: damian s. Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9. Cancer Discov. 2017. PMID: 28183697 Free PMC article. Clinical Trial.
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.
Rodón J, Damian S, Furqan M, García-Donas J, Imai H, Italiano A, Spanggaard I, Ueno M, Yokota T, Veronese ML, Oliveira N, Li X, Gilmartin A, Schaffer M, Goyal L. Rodón J, et al. Among authors: damian s. Nat Med. 2024 Jun;30(6):1645-1654. doi: 10.1038/s41591-024-02934-7. Epub 2024 May 6. Nat Med. 2024. PMID: 38710951 Free PMC article. Clinical Trial.
Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade.
Rivoltini L, Camisaschi C, Fucà G, Paolini B, Vergani B, Beretta V, Damian S, Duca M, Cresta S, Magni M, Leone BE, Castelli C, de Braud F, De Santis F, Di Nicola M. Rivoltini L, et al. Among authors: damian s. Sci Rep. 2024 Feb 9;14(1):3379. doi: 10.1038/s41598-024-54041-9. Sci Rep. 2024. PMID: 38336861 Free PMC article. Clinical Trial.
PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials.
Agnelli L, Villa A, Butt F, Duca M, Guidi A, Carapezza M, Addante M, Lenoci G, O'Regan P, Russo L, Cresta S, Castano A, Ebrahem E, Alfieri S, Patil A, Carter L, Dive C, De Braud FG, Damian S. Agnelli L, et al. Among authors: damian s. Tumori. 2024 Oct;110(5):304-308. doi: 10.1177/03008916241248007. Epub 2024 Apr 27. Tumori. 2024. PMID: 38676437 Free PMC article.
Can a Bullet be Dangerous without a Weapon?
Lupuşoru SI, Damian S, Morà Raşu BC, Grigorovici A. Lupuşoru SI, et al. Among authors: damian s. Chirurgia (Bucur). 2023 Sept;118(eCollection):1. doi: 10.21614/chirurgia.118.eC.2847. Chirurgia (Bucur). 2023. PMID: 37750319 Free article.
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care.
Vingiani A, Agnelli L, Duca M, Lorenzini D, Damian S, Proto C, Niger M, Nichetti F, Tamborini E, Perrone F, Piccolo A, Manoukian S, Azzollini J, Brambilla M, Colombo E, Lopez S, Vernieri C, Marra F, Conca E, Busico A, Capone I, Bozzi F, Angelini M, Devecchi A, Salvatori R, De Micheli V, Baggi A, Pasini S, Jommi C, Ladisa V, Apolone G, De Braud F, Pruneri G. Vingiani A, et al. Among authors: damian s. JCO Precis Oncol. 2023 Jul;7:e2300067. doi: 10.1200/PO.23.00067. JCO Precis Oncol. 2023. PMID: 37487147 Free PMC article.
Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study.
Corradini P, Agrati C, Apolone G, Mantovani A, Giannarelli D, Marasco V, Bordoni V, Sacchi A, Matusali G, Salvarani C, Zinzani PL, Mantegazza R, Tagliavini F, Lupo-Stanghellini MT, Ciceri F, Damian S, Uccelli A, Fenoglio D, Silvestris N, Baldanti F, Piaggio G, Ciliberto G, Morrone A, Locatelli F, Sinno V, Rescigno M, Costantini M; VAX4FRAIL Study Group. Corradini P, et al. Among authors: damian s. Clin Infect Dis. 2023 Feb 8;76(3):e426-e438. doi: 10.1093/cid/ciac404. Clin Infect Dis. 2023. PMID: 35607769 Free PMC article.
44 results